Hoth Therapeutics (HOTH) Competitors $1.88 -0.07 (-3.59%) As of 10:29 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock HOTH vs. IFRX, VXRT, XBIT, IRD, ENTX, CRVO, OKYO, ABOS, IMUX, and ASRTShould you be buying Hoth Therapeutics stock or one of its competitors? The main competitors of Hoth Therapeutics include InflaRx (IFRX), Vaxart (VXRT), XBiotech (XBIT), Opus Genetics (IRD), Entera Bio (ENTX), CervoMed (CRVO), OKYO Pharma (OKYO), Acumen Pharmaceuticals (ABOS), Immunic (IMUX), and Assertio (ASRT). These companies are all part of the "pharmaceutical products" industry. Hoth Therapeutics vs. Its Competitors InflaRx Vaxart XBiotech Opus Genetics Entera Bio CervoMed OKYO Pharma Acumen Pharmaceuticals Immunic Assertio Hoth Therapeutics (NASDAQ:HOTH) and InflaRx (NASDAQ:IFRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, risk, earnings, analyst recommendations and profitability. Which has more risk & volatility, HOTH or IFRX? Hoth Therapeutics has a beta of 0.67, indicating that its stock price is 33% less volatile than the S&P 500. Comparatively, InflaRx has a beta of 1.43, indicating that its stock price is 43% more volatile than the S&P 500. Does the media prefer HOTH or IFRX? In the previous week, Hoth Therapeutics had 5 more articles in the media than InflaRx. MarketBeat recorded 6 mentions for Hoth Therapeutics and 1 mentions for InflaRx. Hoth Therapeutics' average media sentiment score of 0.99 beat InflaRx's score of 0.00 indicating that Hoth Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Hoth Therapeutics Positive InflaRx Neutral Do analysts rate HOTH or IFRX? Hoth Therapeutics currently has a consensus target price of $4.00, suggesting a potential upside of 112.77%. InflaRx has a consensus target price of $6.20, suggesting a potential upside of 359.26%. Given InflaRx's higher possible upside, analysts clearly believe InflaRx is more favorable than Hoth Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hoth Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00InflaRx 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is HOTH or IFRX more profitable? InflaRx's return on equity of -71.76% beat Hoth Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Hoth TherapeuticsN/A -114.32% -105.92% InflaRx N/A -71.76%-57.68% Which has stronger valuation & earnings, HOTH or IFRX? Hoth Therapeutics has higher earnings, but lower revenue than InflaRx. Hoth Therapeutics is trading at a lower price-to-earnings ratio than InflaRx, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHoth TherapeuticsN/AN/A-$8.19M-$1.07-1.76InflaRx$162.83K556.60-$49.85M-$0.80-1.69 Do institutionals and insiders believe in HOTH or IFRX? 7.1% of Hoth Therapeutics shares are held by institutional investors. Comparatively, 42.4% of InflaRx shares are held by institutional investors. 6.9% of Hoth Therapeutics shares are held by company insiders. Comparatively, 16.3% of InflaRx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. SummaryInflaRx beats Hoth Therapeutics on 10 of the 13 factors compared between the two stocks. Get Hoth Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HOTH and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HOTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HOTH vs. The Competition Export to ExcelMetricHoth TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$24.93M$3.11B$5.70B$10.23BDividend YieldN/A2.36%5.68%4.61%P/E Ratio-1.7620.6376.0426.13Price / SalesN/A387.65516.68165.77Price / CashN/A45.9137.5661.52Price / Book2.199.7612.676.32Net Income-$8.19M-$52.73M$3.29B$270.94M7 Day Performance-2.08%0.63%0.09%-0.10%1 Month Performance50.42%6.30%4.14%6.37%1 Year Performance110.67%18.52%65.69%28.45% Hoth Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HOTHHoth Therapeutics3.1612 of 5 stars$1.88-3.6%$4.00+112.8%+126.7%$24.93MN/A-1.764News CoverageIFRXInflaRx2.5036 of 5 stars$1.23-2.4%$6.20+404.1%-11.7%$84.59M$180K-1.5460Gap UpVXRTVaxart2.0323 of 5 stars$0.37-6.0%$2.00+445.6%-56.2%$83.93M$47.40M-1.36120Gap DownXBITXBiotech1.7563 of 5 stars$2.72-1.1%N/A-58.8%$83.84M$4.01M-2.96100Positive NewsIRDOpus Genetics1.8414 of 5 stars$1.37-0.7%$7.33+435.3%N/A$82.67M$10.99M-0.7114ENTXEntera Bio1.3166 of 5 stars$1.83+1.7%$10.00+446.4%-8.2%$82.19M$166K-7.0420Positive NewsCRVOCervoMed3.7187 of 5 stars$8.54-3.5%$19.29+125.8%-46.6%$81.89M$9.74M-3.274Positive NewsOKYOOKYO Pharma2.2574 of 5 stars$2.09-2.8%$7.00+234.9%+108.9%$80.86MN/A0.007News CoverageAnalyst ForecastAnalyst RevisionABOSAcumen Pharmaceuticals2.296 of 5 stars$1.26-4.5%$7.00+455.6%-48.0%$79.96MN/A-0.5520IMUXImmunic2.2472 of 5 stars$0.77-2.7%$8.33+977.8%-43.6%$78.36MN/A-0.8270News CoveragePositive NewsAnalyst ForecastASRTAssertio1.8888 of 5 stars$0.80-1.3%$2.38+195.7%-18.5%$78.27M$117.10M-1.7820 Related Companies and Tools Related Companies InflaRx Alternatives Vaxart Alternatives XBiotech Alternatives Opus Genetics Alternatives Entera Bio Alternatives CervoMed Alternatives OKYO Pharma Alternatives Acumen Pharmaceuticals Alternatives Immunic Alternatives Assertio Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HOTH) was last updated on 9/25/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hoth Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Hoth Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
